Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Target Price at $15.00

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.00.

EPRX has been the topic of a number of recent analyst reports. William Blair initiated coverage on Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They issued an “outperform” rating on the stock. Wall Street Zen raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Zacks Research downgraded Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 17th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Ally Bridge Group NY LLC acquired a new position in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $5,398,000. Guardian Partners Inc. acquired a new position in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $147,000. Ingalls & Snyder LLC raised its stake in Eupraxia Pharmaceuticals by 58.9% during the 3rd quarter. Ingalls & Snyder LLC now owns 59,100 shares of the company’s stock worth $349,000 after buying an additional 21,900 shares during the period. Cibc World Market Inc. raised its stake in Eupraxia Pharmaceuticals by 287.0% during the 4th quarter. Cibc World Market Inc. now owns 58,050 shares of the company’s stock worth $437,000 after buying an additional 43,050 shares during the period. Finally, Quadrature Capital Ltd acquired a new position in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $326,000.

Eupraxia Pharmaceuticals Price Performance

Shares of NASDAQ:EPRX opened at $7.21 on Friday. The company has a market capitalization of $435.70 million, a price-to-earnings ratio of -7.00 and a beta of 1.55. The business’s 50-day moving average is $7.48 and its 200-day moving average is $7.16. Eupraxia Pharmaceuticals has a 1 year low of $3.67 and a 1 year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). Analysts anticipate that Eupraxia Pharmaceuticals will post -0.71 EPS for the current year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.